ArticleFrontiers in nutrition2026
Associations of the composite dietary antioxidant index with all-cause mortality among individuals with psoriasis: a population-based study.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The composite dietary antioxidant index (CDAI) is an effective indicator to evaluate the comprehensive intake of dietary antioxidants in individuals. There is growing evidence suggesting that higher CDAI levels are associated with a reduced risk of diverse health conditions such as hypertension and atherosclerotic cardiovascular disease, as well as with lower mortality risk among the general public. However, its impact on the mortality risk of patients with psoriasis remains unclear. This study aimed to investigate the potential association between CDAI and the risk of death in individuals with psoriasis. Methods: Data extracted from the National Health and Nutrition Examination Survey (NHANES) spanning 2003-2006 and 2009-2014 was enrolled in this research, with mortality data obtained from the National Death Index (NDI) database. We utilized Multivariate COX proportional hazard regression models to investigate the influence of CDAI levels on the death risk from all causes among individuals with psoriasis. We further performed subgroup and sensitivity analyses to verify the reliability of the results. Results: Five hundred patients with psoriasis were finally enrolled in this prospective study. During the follow-up period, 61 deaths occurred. CDAI levels were linked to a reduced death risk in patients with psoriasis, compared to the lowest tertile, the hazard ratios for all-cause mortality were 0.48 (95% CI: 0.20-1.17, Conclusion: Our study found that higher CDAI levels were associated with lower all-cause mortality in patients with psoriasis. Further prospective studies are needed to confirm the role of CDAI in mortality risk in patients with psoriasis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.